Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 360 participants.

Also called NCT03608033

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 360 participants (enrolled count) (from the registry)
Sponsor
Omeros Corporation (from the registry)
Registry
  • NCT NCT03608033
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Australia, Belgium, Bulgaria, Canada, Czechia, Germany, Greece, Hungary, India, Italy, Lithuania, Poland, Singapore, Slovakia, South Korea, Spain, Sweden, Taiwan, Thailand, Türkiye, United Kingdom (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT03608033. Randomized; quadruple masking; primary purpose treatment. Start 2018-04-05 (actual); primary completion 2024-01-12 (actual). Results posted on 2025-12-09.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy
Condition
IgA Nephropathy
Intervention (Biological)
OMS721
Intervention (Other)
Vehicle (D5W or saline)
Lead sponsor
Omeros Corporation (class: industry)

Record details

Record id
cardio:ct-nct03608033
Content hash
3e847d7ed05f0cf1398f8848aaccaddf01a71fe8fdcd749d81ba39dfb6b0b337